Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | PPARG | P37231 | 1/20 | 0.69 |
| ▸ | PPARD | Q03181 | 1/20 | 0.69 |
| ▸ | PPARA | Q07869 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ATM | Q13315 | 2/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | LDHA | P00338 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30644304 | 1.00 | ALDH1A1 (0.69) | ALDH1A1PPARGPPARDPPARACA2 | |
| SCHEMBL3343652 | 0.98 | ALDH1A1 (0.67) | ALDH1A1PPARGPPARDPPARACA2 | |
| SCHEMBL20615143 | 0.87 | CALM1 (0.58) | ALDH1A1PPARGPPARDPPARACA2 | |
| SCHEMBL23375947 | 0.86 | ALDH1A1 (0.53) | ALDH1A1PPARGPPARDPPARACA2 | |
| SCHEMBL5978889 | 0.86 | ALDH1A1 (0.53) | ALDH1A1PPARGPPARDPPARACA2 | |
| SCHEMBL11911908 | 0.85 | ALDH1A1 (0.71) | ALDH1A1PPARGPPARDPPARACA2 | |
| SCHEMBL11911904 | 0.85 | ALDH1A1 (0.71) | ALDH1A1PPARGPPARDPPARACA2 | |
| SCHEMBL4775183 | 0.84 | MEN1 (0.53) | ALDH1A1PPARGPPARDPPARACA2 | |
| SCHEMBL15174299 | 0.84 | ALDH1A1 (0.51) | ALDH1A1PPARGPPARDPPARACA2 | |
| SCHEMBL195794 | 0.84 | ALDH1A1 (0.50) | ALDH1A1PPARGPPARDPPARACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102531813-B | Process for continuous hydrogenation or hydrogenating amination | BASF SE | 2014-09-24 | — | — | CN | claimed |
| US-8557985-B2 | Process for continuous hydrogenation or hydrogenating amination | BASF SE (DE) | 2013-10-15 | — | — | US | claimed |
| US-8198295-B2 | Benzonaphthyridines | NYCOMED GMBH (DE) | 2012-06-12 | — | — | US | claimed |
| US-20090030029-A1 | Novel benzonaphthyridines | ALTANA PHARMA AG (DE) | 2009-01-29 | — | — | US | claimed |
| US-7470704-B2 | Benzonaphthyridines | NYCOMED GMBH (DE) | 2008-12-30 | — | — | US | claimed |
| EP-1537109-B1 | NOVEL BENZONAPHTHYRIDINES | ALTANA PHARMA AG (DE) | 2007-04-18 | — | — | EP | claimed |
| US-20060167034-A1 | Novel benzonaphthyridines | ALTANA PHARMA AG (DE) | 2006-07-27 | — | — | US | claimed |
| EP-1537109-A1 | NOVEL BENZONAPHTHYRIDINES | ALTANA Pharma AG (DE) | 2005-06-08 | — | — | EP | claimed |
| WO-2004022557-A1 | NOVEL BENZONAPHTHYRIDINES | ALTANA PHARMA AG (DE) | 2004-03-18 | — | — | WO | claimed |
| US-20010031758-A1 | Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands | NEUROGEN CORPORATION | 2001-10-18 | — | — | US | claimed |
| EP-0357565-B1 | New process for the synthesis of the levodopa | MINI RICERCA SCIENT TECNOLOG (IT) | 1994-09-14 | — | — | EP | claimed |
| EP-0389876-B1 | NEW PROCESS FOR THE SYNTHESIS OF THE N-METHYL-3,4-DIMETHOXYPHENYLETHYLAMINE | Alfa Chemicals Italiana S.r.l. (IT) | 1993-08-04 | — | — | EP | claimed |
| US-5057624-A | PROCESS FOR THE SYNTHESIS OF THE N-METHYL-3,4-DIMETHOXYPHENYLETHYLAMINE | ALFA WASSERMANN S.P.A. (IT) | 1991-10-15 | — | — | US | claimed |
| US-4962223-A | Process for the synthesis of the levodopa | Ministero dell'Universita e delle Ricerca Scientifica e Tecnologica (IT) | 1990-10-09 | — | — | US | claimed |
| EP-0389876-A1 | New process for the synthesis of the N-methyl-3,4-dimethoxyphenylethylamine | Alfa Chemicals Italiana S.r.l. (IT) | 1990-10-03 | — | — | EP | claimed |
| JP-2231457-A | — | — | None | — | — | JP | disclosed |
| CN-122059867-A | Substituted indole compounds, preparation method and application thereof | 安徽医科大学 | 2026-05-19 | — | — | CN | disclosed |
| EP-0042093-A2 | 4-Aralkyl-1,4-dihydropyridines, processes for praparing them, their use as medicines and preparation thereof | BAYER AG (DE) | 1981-12-23 | — | — | EP | disclosed |
| US-4147780-A | α-Amino-phosphonous acids for inhibiting bacteria and yeast | CIBA-GEIGY CORPORATION (US) | 1979-04-03 | — | — | US | disclosed |
| US-3962281-A | METHOD OF PREPARING ALDEHYDES | SAGAMI CHEMICAL RESEARCH CENTER (JA) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167034-A1 | Novel benzonaphthyridines | PDE4A, PDE3A, PDE3B | ALDH1A1 670/4885PPARG 2285/4885PPARD 1267/4885 |
| US-20010031758-A1 | Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands | NPY1R, NPY2R, NPY5R | ALDH1A1 3312/4885PPARG 1306/4885PPARD 945/4885 |
| US-20090030029-A1 | Novel benzonaphthyridines | PDE4A, PDE3A, PDE3B | ALDH1A1 670/4885PPARG 2285/4885PPARD 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.